Kala Bio, INC Form 4 insider transactions

KALA BIO, Inc. CEO David E. Lazar's convertible loan of up to $375,000 was fully repaid in cash by the issuer on December 18, 2025, foregoing conversion into common stock.

KALA BIO's CEO, David E. Lazar, acquired 900,000 shares of Series AA Convertible Preferred Stock for $1.8 million, with plans for a further $4.2 million investment.

KALA BIO, Inc. Director Mark T. Iwicki reported the sale of 154,894 shares of common stock at a weighted average price of $0.81 per share.

KALA BIO's Chief Financial Officer, Mary Reumuth, reported the sale of 33,197 common shares under a pre-arranged trading plan.

KALA BIO Director Todd Bazemore sold 47,768 shares of common stock at a weighted average price of $0.83 per share, reducing his direct beneficial ownership.

KALA BIO's Head of R&D and Chief Medical Officer, Romulus K. Brazzell, has reported a planned sale of 46,748 shares of common stock at a weighted average price of $0.83 per share on October 22, 2025, under a Rule 10b5-1 trading plan.

KALA BIO's Chief Business Officer, Darius Kharabi, sold 20,806 shares of common stock for a weighted average price of $0.83 per share.

Baker Bros. Advisors, a former 10% owner, significantly reduced its stake in KALA BIO, Inc. through multiple stock sales in late September and early October 2025.

KALA BIO, Inc.'s President and CEO, Todd Bazemore, was granted 180,000 stock options with an exercise price of $11.22, vesting over four years.

KALA BIO, Inc.'s Chief Business Officer, Darius Kharabi, sold 4,511 shares of common stock for tax withholding obligations related to RSU vesting, as disclosed in a recent SEC Form 4 filing.

KALA BIO's Chief Financial Officer, Mary Reumuth, sold 3,631 shares of common stock on June 24, 2025, at a weighted average price of $4.01 per share, to satisfy tax withholding obligations.

KALA BIO, Inc.'s Interim CEO, President, and COO, Todd Bazemore, sold 4,058 shares of common stock for tax withholding purposes related to RSU vesting.

Romulus K. Brazzell, Head of Research and Development and Chief Medical Officer at KALA BIO, Inc., sold 5,251 shares of common stock for tax withholding purposes.

KALA BIO, Inc. Director Mark T. Iwicki sold 13,227 shares of common stock on June 24, 2025, at a weighted average price of $4.01 per share, primarily to satisfy tax withholding obligations related to vested restricted stock units.

KALA BIO, Inc. Director Howard B. Rosen was granted 2,450 restricted stock units and 5,450 stock options, increasing his beneficial ownership in the company.

KALA BIO, Inc. Director Mark T. Iwicki was granted 2,450 restricted stock units and 5,450 stock options, aligning his interests with shareholders.

KALA BIO, Inc. Director Marjan Farid was granted 2,450 restricted stock units and options to purchase 5,450 shares of common stock on June 15, 2025, as part of the company's equity incentive plan.

KALA BIO, Inc. Director Gregory D. Perry was granted 2,450 restricted stock units and options to purchase 5,450 shares of common stock, effective June 15, 2025, as part of the company's equity incentive plan.

KALA BIO, Inc. Director C. Daniel Myers was granted 2,450 restricted stock units and options to purchase 5,450 shares of common stock on June 15, 2025, as disclosed in a recent SEC Form 4 filing.

KALA BIO, Inc. Director Andrew Koven was granted 3,050 restricted stock units and 6,850 stock options, increasing his beneficial ownership in the company.

KALA BIO, Inc. Director Mark T. Iwicki filed an amended Form 4 to clarify a previously reported acquisition of common stock was, in fact, a disposition of 10,866 shares at a weighted average price of $3.74 to cover tax obligations.

KALA BIO's Chief Business Officer, Darius Kharabi, sold 730 shares of common stock on June 3, 2025, to satisfy tax withholding obligations related to restricted stock unit vesting.

KALA BIO, Inc.'s Chief Financial Officer, Mary Reumuth, sold 2,850 shares of common stock on June 3, 2025, to satisfy tax withholding obligations related to the vesting of her restricted stock units.

Todd Bazemore, Interim Chief Executive Officer of KALA BIO, Inc., sold 3,390 shares of common stock on June 3, 2025, to cover tax withholding obligations related to the vesting of restricted stock units.

KALA BIO's Head of R&D and Chief Medical Officer, Romulus K Brazzell, sold 3,687 shares of common stock on June 3, 2025, at a weighted average price of $3.74, as part of a pre-arranged 10b5-1 plan to cover tax withholding obligations.

KALA BIO, Inc. Director Mark T. Iwicki sold 10,866 shares of common stock for tax withholding purposes, as disclosed in a recent SEC Form 4 filing.

Todd Bazemore, Interim CEO, President, and COO of KALA BIO, Inc., reports the grant of a stock option for 45,200 shares.

A KALA Bio executive filed an amended SEC Form 4 to correct the number of shares beneficially owned after a previous filing error.

Chief Business Officer of Kala Bio, Darius Kharabi, reports the acquisition of restricted stock units, the sale of common stock, and the grant of stock options.

Todd Bazemore, President and COO of Kala Bio, reports the acquisition of restricted stock units, the sale of common stock, and the grant of stock options.